Advertise here

DrugPatentWatch Information on Approved Drugs and Drug Products

This newsletter is a free service of DrugPatentWatch
DrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents

Drug Patent Expirations for May 2013

TradenameApplicantGeneric Name Patent Expiration
GEMZAR
Lilly
gemcitabine hydrochloride
May 7, 2013
HUMALOG PEN
Lilly
insulin lispro recombinant
May 7, 2013
HUMALOG
Lilly
insulin lispro recombinant
May 7, 2013
HUMALOG MIX 75/25
Lilly
insulin lispro protamine recombinant; insulin lispro recombinant
May 7, 2013
HUMALOG MIX 50/50
Lilly
insulin lispro protamine recombinant; insulin lispro recombinant
May 7, 2013
PREVACID
Takeda Pharms Usa
lansoprazole
May 7, 2013
HUMALOG KWIKPEN
Lilly
insulin lispro recombinant
May 7, 2013
HUMALOG MIX 75/25 KWIKPEN
Lilly
insulin lispro protamine recombinant; insulin lispro recombinant
May 7, 2013
HUMALOG MIX 50/50 KWIKPEN
Lilly
insulin lispro protamine recombinant; insulin lispro recombinant
May 7, 2013
ZAVESCA
Actelion Pharms Ltd
miglustat
May 13, 2013
DEPOCYT
Pacira Pharms Inc
cytarabine
May 14, 2013
ZOMIG-ZMT
Astrazeneca
zolmitriptan
May 14, 2013
ZOMIG
Ipr
zolmitriptan
May 14, 2013
ZOMIG
Astrazeneca
zolmitriptan
May 14, 2013
OSMOPREP
Salix Pharms
sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
May 18, 2013
VISICOL
Salix Pharms
sodium phosphate, dibasic anhydrous; sodium phosphate, monobasic, monohydrate
May 18, 2013
ADRENACLICK
Amedra Pharms
epinephrine
May 27, 2013

*Drugs may be covered by multiple patents or regulatory protections. See the DrugPatentWatch database for complete details.


DrugPatentWatch Infographics

Which pharmaceutical companies recieved the most drug approvals last
year

Which Companies had the Most Drug Approvals Last Year?

More infographics »

DrugPatentWatch Serves Your Competitive Intelligence Needs

Subscribers have access to valuable datasets, including:
  • Patent litigation
  • Clinical trial information
  • International patent families
  • International patent priority and PCT information
  • Patent maintenance
  • Full-text patent downloads
  • Paragraph IV challenges
  • Tentative approvals
  • Drug Master Files
  • Dynamic search capabilities with data export
  • More…
See the Database Preview and Plan Comparison. Contact Us with any questions.

If this newsletter has been forwarded to you and you would like to receive regular updates by email, go to http://www.DrugPatentWatch.com/newsletter


The above list does not discriminate between dominant and non-dominant patents. Drugs listed above may be protected by additional patents and other regulatory protections. See the DrugPatentWatch database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
All trademarks and applicant names are the property of their respective owners or licensors.

Sign up for a free trial

First name
Last name
Email address

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639

`abc